title: Diverse ways of perturbing the human arachidonic acid metabolic network to control inflammation.
abstract: Inflammation and other common disorders including diabetes, cardiovascular disease, and cancer are often the result of several molecular abnormalities and are not likely to be resolved by a traditional single-target drug discovery approach. Though inflammation is a normal bodily reaction, uncontrolled and misdirected inflammation can cause inflammatory diseases such as rheumatoid arthritis and asthma. Nonsteroidal anti-inflammatory drugs including aspirin, ibuprofen, naproxen, or celecoxib are commonly used to relieve aches and pains, but often these drugs have undesirable and sometimes even fatal side effects. To facilitate safer and more effective anti-inflammatory drug discovery, a balanced treatment strategy should be developed at the biological network level. In this Account, we focus on our recent progress in modeling the inflammation-related arachidonic acid (AA) metabolic network and subsequent multiple drug design. We first constructed a mathematical model of inflammation based on experimental data and then applied the model to simulate the effects of commonly used anti-inflammatory drugs. Our results indicated that the model correctly reproduced the established bleeding and cardiovascular side effects. Multitarget optimal intervention (MTOI), a Monte Carlo simulated annealing based computational scheme, was then developed to identify key targets and optimal solutions for controlling inflammation. A number of optimal multitarget strategies were discovered that were both effective and safe and had minimal associated side effects. Experimental studies were performed to evaluate these multitarget control solutions further using different combinations of inhibitors to perturb the network. Consequently, simultaneous control of cyclooxygenase-1 and -2 and leukotriene A4 hydrolase, as well as 5-lipoxygenase and prostaglandin E2 synthase were found to be among the best solutions. A single compound that can bind multiple targets presents advantages including low risk of drug-drug interactions and robustness regarding concentration fluctuations. Thus, we developed strategies for multiple-target drug design and successfully discovered several series of multiple-target inhibitors. Optimal solutions for a disease network often involve mild but simultaneous interventions of multiple targets, which is in accord with the philosophy of traditional Chinese medicine (TCM). To this end, our AA network model can aptly explain TCM anti-inflammatory herbs and formulas at the molecular level. We also aimed to identify activators for several enzymes that appeared to have increased activity based on MTOI outcomes. Strategies were then developed to predict potential allosteric sites and to discover enzyme activators based on our hypothesis that combined treatment with the projected activators and inhibitors could balance different AA network pathways, control inflammation, and reduce associated adverse effects. Our work demonstrates that the integration of network modeling and drug discovery can provide novel solutions for disease control, which also calls for new developments in drug design concepts and methodologies. With the rapid accumulation of quantitative data and knowledge of the molecular networks of disease, we can expect an increase in the development and use of quantitative disease models to facilitate efficient and safe drug discovery.
authors.affiliation: †BNLMS, State Key Laboratory for Structural Chemistry of Unstable and Stable Species, College of Chemistry and Molecular Engineering, ‡Center for Quantitative Biology, and §Peking-Tsinghua Center for Life Sciences, Peking University, Beijing 100871, China.
authors.forename: Hu
authors.initials: H
authors.lastname: Meng
authors.affiliation: †BNLMS, State Key Laboratory for Structural Chemistry of Unstable and Stable Species, College of Chemistry and Molecular Engineering, ‡Center for Quantitative Biology, and §Peking-Tsinghua Center for Life Sciences, Peking University, Beijing 100871, China.
authors.forename: Ying
authors.initials: Y
authors.lastname: Liu
authors.affiliation: †BNLMS, State Key Laboratory for Structural Chemistry of Unstable and Stable Species, College of Chemistry and Molecular Engineering, ‡Center for Quantitative Biology, and §Peking-Tsinghua Center for Life Sciences, Peking University, Beijing 100871, China.
authors.forename: Luhua
authors.initials: L
authors.lastname: Lai
mesh_terms: D000893:Anti-Inflammatory Agents / Q000737:chemistry / Q000378:metabolism; D001094:Arachidonate 5-Lipoxygenase / Q000737:chemistry / Q000378:metabolism; D016718:Arachidonic Acid / Q000737:chemistry / Q000378:metabolism*; D001665:Binding Sites; D051545:Cyclooxygenase 1 / Q000737:chemistry / Q000378:metabolism; D051546:Cyclooxygenase 2 / Q000737:chemistry / Q000378:metabolism; D015195:Drug Design; D004851:Epoxide Hydrolases / Q000737:chemistry / Q000378:metabolism; D006801:Humans; D007249:Inflammation / Q000517:prevention & control*; D019746:Intramolecular Oxidoreductases / Q000737:chemistry / Q000378:metabolism; D008516:Medicine, Chinese Traditional; D053858:Metabolic Networks and Pathways; D062105:Molecular Docking Simulation; D009010:Monte Carlo Method; D000071876:Prostaglandin-E Synthases; D017434:Protein Structure, Tertiary
chemical_list: D000893:Anti-Inflammatory Agents; D016718:Arachidonic Acid; D001094:Arachidonate 5-Lipoxygenase; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2; D004851:Epoxide Hydrolases; D019746:Intramolecular Oxidoreductases; D000071876:Prostaglandin-E Synthases; C043134:leukotriene A4 hydrolase